Asset
BULOXIBUTID
VICORE PHARMA HOLDING AB AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06588686 | phase2 | active_not_recruiting | 2024-12-09 | 2027-05-01 | Vicore Pharma AB | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. |
| NCT05831644 | phase1 | completed | 2023-03-31 | 2023-06-16 | Vicore Pharma AB | A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes |
| NCT04880642 | phase3 | completed | 2021-09-16 | 2022-04-25 | Vicore Pharma AB | A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects |
| NCT04388176 | phase2 | completed | 2020-01-03 | 2020-12-14 | Vicore Pharma AB | Cold Challenge With C21 in RP |
| NCT05277922 | phase1 | completed | 2022-04-28 | 2022-05-11 | Vicore Pharma AB | Effect of C21 on Forearm Blood Flow |
FDA applications (0)
This company has no applications containing this asset.